Colospa - myotropic spasmolytic with selective effect on unstriated muscles of digestive tract. Eliminates a spasm, without influencing a normal peristaltics of intestines. Unlike cholinolytic medicine, Colospa does not affect at muscarinic receptor and does not cause characteristic of antispasmodics with muscarinic receptor action of side effects (feeling of dryness in a mouth, vision disorders, an urination delay) that allows for patients to take it at prostatauxe or glaucoma. Taking of Colospa is not followed by development of reflex hypotonia of intestines.

Prevents the occurrence of epileptic seizures, allodynia and hyperalgesia, and especially the pain response in different models of neuropathic pain. In addition,it reduces the pain response to peripheral inflammation, but does not affect the immediate behavior caused by pain.